API | baloxavir marboxil

baloxavir marboxil (xofluza) Report issue

Small molecule Approved ^FDA Priority Review ^FDA

AACT Drugs@FDA

Active Ingredient History

NOW

Baloxavir marboxil, sold under the brand name Xofluza, is an antiviral medication for treatment of influenza A and influenza B flu. It was approved for medical use both in Japan and in the United States in 2018, and is taken as a single dose by mouth. It may reduce the duration of flu symptoms by about a day, but is prone to selection of resistant mutants that render it ineffectual. ^Wikipedia

Chemistry

SMILES: OC1=C2N(C=CC1=O)N([C@@H]3COCCN3C2=O)[C@@H]4C5=CC=CC=C5SCC6=C(F)C(F)=CC=C46
InChIKey: FIDLLEYNNRGVFR-CTNGQTDRSA-N
Mol. Mass: 483.487
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanism of Action:
Multi-specific: Missing data
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

Drug Pricing (per unit)

United States

$55.3200 - $73.5449

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

baloxavir marboxil | s-033188

Organizations (10)

Research & Development (10)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (1)

Influenza A virus (approved 2020)

Experimental Indications - Clinical Trial Phases 1-4 (3)

Influenza, Human (Phase 4)

Lymphoma (Phase 2)

Respiratory Tract Infections (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 13
# of Trial Organizations: 10

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue